Neurofilament in clinical practice: Is the multiple sclerosis community ready?-Reference-Cited by-同舟云学术

Neurofilament in clinical practice: Is the multiple sclerosis community ready?

Published:2024-04-11 Issue:6 Volume:30 Page:643-645
ISSN:1352-4585
Container-title:Multiple Sclerosis Journal
language:en
Short-container-title:Mult Scler

Author:

Moccia Marcello¹²^ORCID,Terracciano Daniela³,Brescia Morra Vincenzo²⁴,Castaldo Giuseppe¹⁵

Affiliation:

1. Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy

2. Multiple Sclerosis Unit, Policlinico Federico II University Hospital, Naples, Italy

3. Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy

4. Department of Neuroscience, Reproductive Science and Odontostomatology, University of Naples Federico II, Naples, Italy

5. Centre for Advanced Biotechnology (CEINGE), Naples, Italy

Publisher

SAGE Publications

Link

https://journals.sagepub.com/doi/pdf/10.1177/13524585241246536

Reference23 articles.

1. Neurofilament light chain as neuronal injury marker – what is needed to facilitate implementation in clinical laboratory practice?

2. Serum neurofilament light in MS: The first true blood-based biomarker?

3. Consortium of Multiple Sclerosis Centers Neurofilament Consensus Paper. Neurofilament biomarkers in multiple sclerosis. CMSC best practices for the use of serum neurofilament (sNfL) in MS management, 2024, https://mscare.sharefile.com/d-s60a6a95b73684d83873c6d9cab9d66b8

4. Neurofilament light chain as a biomarker in neurological disorders

5. Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Does serum neurofilament light chain measurement influence therapeutic decisions in multiple sclerosis?;Multiple Sclerosis and Related Disorders;2024-10

2. Clinical utility of the Lumipulse™ immunoassay for plasma neurofilament light chain in multiple sclerosis;Journal of the Neurological Sciences;2024-08

3. Real-World Study of Serum Neurofilament Light Chain Levels in Ocrelizumab-Treated People with Relapsing Multiple Sclerosis;Journal of Personalized Medicine;2024-06-27

4. The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis;Journal of Neurology;2024-05-23